In renal cell carcinoma patients, for example, mutations in CDKN2A have been linked to reductions in ICI-related clinical benefit52, whereas they reportedly had no effect in melanoma53. The gene discussed is CDKN2A; the disease is hereditary clear cell renal cell carcinoma.